-
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
-
ChemBase ID:
72789
-
Molecular Formular:
C24H30O6
-
Molecular Mass:
414.4914
-
Monoisotopic Mass:
414.20423868
-
SMILES and InChIs
SMILES:
C1C(=O)C=C2[C@](C1)([C@]13[C@@H]([C@@H](C2)C(=O)OC)[C@H]2[C@](C[C@@H]1O3)([C@@]1(CC2)CCC(=O)O1)C)C
Canonical SMILES:
COC(=O)[C@@H]1CC2=CC(=O)CC[C@@]2([C@@]23[C@@H]1[C@@H]1CC[C@]4([C@@]1(C)C[C@@H]3O2)CCC(=O)O4)C
InChI:
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
InChIKey:
JUKPWJGBANNWMW-VWBFHTRKSA-N
-
Cite this record
CBID:72789 http://www.chembase.cn/molecule-72789.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
|
|
|
IUPAC Traditional name
|
|
Synonyms
|
Inspra
|
Epoxymexrenone
|
CGP30083
|
SC-66110
|
Eplerenone
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
15.113572
|
H Acceptors
|
4
|
H Donor
|
0
|
LogD (pH = 5.5)
|
2.3314128
|
LogD (pH = 7.4)
|
2.3314128
|
Log P
|
2.3314128
|
Molar Refractivity
|
106.6777 cm3
|
Polarizability
|
42.67 Å3
|
Polar Surface Area
|
82.2 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
PROPERTIES
PROPERTIES
Safety Information
Product Information
Bioassay(PubChem)
Storage Condition
|
-20°C
|
Show
data source
|
|
Salt Data
|
Free Base
|
Show
data source
|
|
DETAILS
DETAILS
Selleck Chemicals
Selleck Chemicals -
S1707
|
Research Area: Cardiovascular Disease Biological Activity: Eplerenone is an aldosterone antagonist with an IC50 of 0.36 μM. It is used as an adjunct in the management of chronic heart failure. It is similar to the diuretic spironolactone, though it may be more specific for the mineralocorticoid receptor and is specifically marketed for reducing cardiovascular risk in patients following myocardial infarction. [1] |
PATENTS
PATENTS
PubChem Patent
Google Patent